Bioniche Life Scienc (BNHLF) 0.2304 $BNHLF
IIROC Trade Resumption - TST
CNW Group - Fri Feb 13, 9:08AM CST
Trading resumes in:
TST.TO: 0.29 (-0.02)
IIROC Trade Resumption - Telesta Therapeutics Inc.
Newsfile Corp - Fri Feb 13, 9:06AM CST
Trading resumes in:
Telesta Therapeutics Publishes its 6 Month Financial Results to December 31, 2014 and Provides Important Corporate Updates
CNW Group - Fri Feb 13, 8:53AM CST
Telesta Therapeutics Inc. (TSX:TST; PNK:BNHLF) today issued its financial statements and associated Management's Discussion and Analysis (MD&A), for the 6 month period ended December 31, 2014. In addition Telesta provided key corporate updates covering:
TST.TO: 0.29 (-0.02)
IIROC Trading Halt - TST
CNW Group - Fri Feb 13, 8:29AM CST
The following issues have been halted by IIROC:
TST.TO: 0.29 (-0.02)
IIROC Trade Halt - Telesta Therapeutics Inc.
Newsfile Corp - Fri Feb 13, 8:28AM CST
The following issues have been halted by IIROC:
Telesta Therapeutics Announces Key Clinical & Corporate Updates
PR Newswire - Mon Dec 01, 8:29AM CST
Telesta Therapeutics Inc. (TSX: TST; PNK: BNHLF) (Formerly Bioniche Life Sciences Inc. TST:BNC) today affirmed that they remain on track with their internal objective of filing a Biologics License Application (BLA) for marketing approval with the US Food and Drug Administration (FDA) for MCNA 1 prior to March 31, 2015. Two recent key accomplishments include the completion of both a pre-BLA meeting with the US FDA and a mock-audit of Telesta's MCNA manufacturing facility. As the result of the pre-BLA meeting, Telesta received written answers and verbal feedback to a number of clinical, manufacturing and regulatory items related to the filing of their BLA while the manufacturing "mock-audit" saw a third party firm complete a detailed and exhaustive review intended to simulate the type of audit that Telesta is expected to be subject to, by the FDA, during the course of a BLA review process.
TST.TO: 0.29 (-0.02)
Bioniche Life Sciences Inc. Rebrands as Telesta Therapeutics Inc.
PR Newswire - Mon Nov 24, 8:00AM CST
Bioniche Life Sciences Inc. (TSX: BNC PNK: BNHLF) Bioniche Life Sciences today announced the accomplishment of another major milestone in the execution of its strategic plan to become a focused late stage human therapeutics company with near term commercial potential. Effective immediately, the Company will begin operating under its new corporate name and identity, Telesta Therapeutics Inc.
BNC.TO: 0.21 (unch)
Bioniche Life Sciences Inc. announces results of annual general meeting of shareholders
PR Newswire - Thu Nov 13, 10:10AM CST
Bioniche Life Sciences Inc. (TSX: BNC) ("Bioniche" or the "Company"
is pleased to provide the results from its annual general meeting of shareholders held November 12, 2014 in Toronto (the "Meeting" .
BNC.TO: 0.21 (unch)
Bioniche Life Sciences Inc. Reports MCNA Update & First Quarter Results
PR Newswire - Wed Nov 12, 6:55AM CST
(all figures are in Canadian dollars unless otherwise noted)
BNC.TO: 0.21 (unch)
Orphan Drug Designation Update and Annual General Meeting Reminder
PR Newswire - Wed Nov 05, 3:35PM CST
Bioniche Life Sciences Inc. (TSX: BNC) today announced that it will not continue its dialogue with the US Food & Drug Administration (FDA) concerning its request for Orphan Drug Designation (ODD) for its bladder cancer therapeutic, Mycobacterium phlei cell-wall - nucleic acid complex (MCNA). The FDA has indicated that it could not grant Bioniche's request for ODD at this time, because the Company had not established to its satisfaction that the target population estimate for MCNA did not exceed 200,000 potential patients in the US.
BNC.TO: 0.21 (unch)
Bioniche Life Sciences Inc. to Publish Comprehensive Phase 3 Clinical Trial Results In The Journal of Urology
PR Newswire - Fri Oct 10, 7:00AM CDT
Bioniche Life Sciences Inc. (TSX: BNC: PNK:BNHLF) today announced that The Journal of Urology has accepted for publication a manuscript entitled: Efficacy and Safety of MCNA in Patients with Non-Muscle Invasive Bladder Cancer at High-Risk of Recurrence and Progression Who Have Failed Treatment with BacillusCalmette-Guérin. An unedited version of the paper is now available for review and citation online at www.jurology.com (http://www.jurology.com/article/S0022-5347(14)04590-X/abstract); with an expected in print date tentatively scheduled for April 2015.
BNC.TO: 0.21 (unch)
Veterinary Purchasing Company Limited Appoints a New CEO
CNW Group - Wed Oct 01, 8:00AM CDT
The Board of Directors of Veterinary Purchasing Company Limited (VPCL) today announced the appointment of a new Chief Executive Officer. Mr. Rick Culbert takes over the role from Mr. Brendan Ginty, who is retiring after 39 years of leadership.
Bioniche Life Sciences Inc. Reports Fiscal 2014 Year-End Results
PR Newswire - Fri Sep 26, 4:12PM CDT
(all figures are in Canadian dollars unless otherwise noted)
BNC.TO: 0.21 (unch)
Bioniche Life Sciences Receives Coverage as Highly Undervalued Biopharmaceutical
Marketwire - Wed Sep 17, 9:20AM CDT
Bioniche Life Sciences, Inc. (PINKSHEETS: BNHLF) (TSX: BNC), a clinical stage Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary and innovative therapies for the global human health market, has been featured in a new article that highlights this busy but "under the radar" company with quite a story to tell. Sujan Lahiri, an independent market researcher with a focus on small-cap stocks, released his in-depth analysis on Bioniche today on Seeking Alpha.
BNC.TO: 0.21 (unch)
Global N-acetylcysteine Market Report 2014-2019
M2 - Tue Sep 16, 9:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f6gj3d/global) has announced the addition of the "Global N-acetylcysteine Industry Report 2014" report to their offering. The Global N-acetylcysteine Industry Report 2014 is a professional and in-depth study on the current state of the global N-acetylcysteine industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The N-acetylcysteine market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. N-acetylcysteine industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. The report focuses on twenty industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The N-acetylcysteine industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered: - N-acetylcysteine Industry Overview - Global N-acetylcysteine Market Status Analysis - Major Regions N-acetylcysteine Market Status Analysis - Major Countries N-acetylcysteine Market Status and Analysis - Major Companies N-acetylcysteine Market Status and Analysis - N-acetylcysteine Industry Chain and Marketing Channels Analysis - N-acetylcysteine Industry Segment Market Analysis - N-acetylcysteine Industry Development Trend - N-acetylcysteine New Project Investment Feasibility Analysis - Global N-acetylcysteine Industry Research Conclusions Companies Mentioned - BASF - Bioniche Life Sciences - Cumberland Pharmaceuticals - Donboo Amino Acid - Hubei Jusheng Technology - Hubei Shengbaolai Biological Technology - Manus Aktteva Biopharma Llp - Ningbo Create-Bio Engineering - Ningbo Zhenhai Haide Amino Acid - Swacker Ag - Wuxi Enovo Chemical - Wuhan Grand Hoyo - Wuhan Hezhong Bio-Chemical - Wuhan Lullaby Pharmaceutical Chemical - Xys - Xinyi Hanling Biological Engineering - Zambon - Zhangjiagang Specom Biochemical - Zhangjiagang Huachang Pharmaceutical - Zhangjiagang Shuguang Biological For more information visit http://www.researchandmarkets.com/research/f6gj3d/global
CPIX: 5.90 (+0.04)
IIROC Trade Resumption - Bioniche Life Sciences Inc.
Newsfile Corp - Fri Aug 22, 1:12PM CDT
Trading resumes in:
IIROC Trade Halt - Bioniche Life Sciences Inc.
Newsfile Corp - Thu Aug 21, 2:29PM CDT
The following issues have been halted by IIROC:
IIROC Trade Resumption - TST
CNW Group - Fri Feb 13, 9:08AM CST
Trading resumes in:
TST.TO: 0.29 (-0.02)
IIROC Trade Resumption - Telesta Therapeutics Inc.
Newsfile Corp - Fri Feb 13, 9:06AM CST
Trading resumes in:
Telesta Therapeutics Publishes its 6 Month Financial Results to December 31, 2014 and Provides Important Corporate Updates
CNW Group - Fri Feb 13, 8:53AM CST
Telesta Therapeutics Inc. (TSX:TST; PNK:BNHLF) today issued its financial statements and associated Management's Discussion and Analysis (MD&A), for the 6 month period ended December 31, 2014. In addition Telesta provided key corporate updates covering:
TST.TO: 0.29 (-0.02)
IIROC Trading Halt - TST
CNW Group - Fri Feb 13, 8:29AM CST
The following issues have been halted by IIROC:
TST.TO: 0.29 (-0.02)
IIROC Trade Halt - Telesta Therapeutics Inc.
Newsfile Corp - Fri Feb 13, 8:28AM CST
The following issues have been halted by IIROC:
Telesta Therapeutics Announces Key Clinical & Corporate Updates
PR Newswire - Mon Dec 01, 8:29AM CST
Telesta Therapeutics Inc. (TSX: TST; PNK: BNHLF) (Formerly Bioniche Life Sciences Inc. TST:BNC) today affirmed that they remain on track with their internal objective of filing a Biologics License Application (BLA) for marketing approval with the US Food and Drug Administration (FDA) for MCNA 1 prior to March 31, 2015. Two recent key accomplishments include the completion of both a pre-BLA meeting with the US FDA and a mock-audit of Telesta's MCNA manufacturing facility. As the result of the pre-BLA meeting, Telesta received written answers and verbal feedback to a number of clinical, manufacturing and regulatory items related to the filing of their BLA while the manufacturing "mock-audit" saw a third party firm complete a detailed and exhaustive review intended to simulate the type of audit that Telesta is expected to be subject to, by the FDA, during the course of a BLA review process.
TST.TO: 0.29 (-0.02)
Bioniche Life Sciences Inc. Rebrands as Telesta Therapeutics Inc.
PR Newswire - Mon Nov 24, 8:00AM CST
Bioniche Life Sciences Inc. (TSX: BNC PNK: BNHLF) Bioniche Life Sciences today announced the accomplishment of another major milestone in the execution of its strategic plan to become a focused late stage human therapeutics company with near term commercial potential. Effective immediately, the Company will begin operating under its new corporate name and identity, Telesta Therapeutics Inc.
BNC.TO: 0.21 (unch)
Bioniche Life Sciences Inc. announces results of annual general meeting of shareholders
PR Newswire - Thu Nov 13, 10:10AM CST
Bioniche Life Sciences Inc. (TSX: BNC) ("Bioniche" or the "Company"
is pleased to provide the results from its annual general meeting of shareholders held November 12, 2014 in Toronto (the "Meeting" . BNC.TO: 0.21 (unch)
Bioniche Life Sciences Inc. Reports MCNA Update & First Quarter Results
PR Newswire - Wed Nov 12, 6:55AM CST
(all figures are in Canadian dollars unless otherwise noted)
BNC.TO: 0.21 (unch)
Orphan Drug Designation Update and Annual General Meeting Reminder
PR Newswire - Wed Nov 05, 3:35PM CST
Bioniche Life Sciences Inc. (TSX: BNC) today announced that it will not continue its dialogue with the US Food & Drug Administration (FDA) concerning its request for Orphan Drug Designation (ODD) for its bladder cancer therapeutic, Mycobacterium phlei cell-wall - nucleic acid complex (MCNA). The FDA has indicated that it could not grant Bioniche's request for ODD at this time, because the Company had not established to its satisfaction that the target population estimate for MCNA did not exceed 200,000 potential patients in the US.
BNC.TO: 0.21 (unch)
Bioniche Life Sciences Inc. to Publish Comprehensive Phase 3 Clinical Trial Results In The Journal of Urology
PR Newswire - Fri Oct 10, 7:00AM CDT
Bioniche Life Sciences Inc. (TSX: BNC: PNK:BNHLF) today announced that The Journal of Urology has accepted for publication a manuscript entitled: Efficacy and Safety of MCNA in Patients with Non-Muscle Invasive Bladder Cancer at High-Risk of Recurrence and Progression Who Have Failed Treatment with BacillusCalmette-Guérin. An unedited version of the paper is now available for review and citation online at www.jurology.com (http://www.jurology.com/article/S0022-5347(14)04590-X/abstract); with an expected in print date tentatively scheduled for April 2015.
BNC.TO: 0.21 (unch)
Veterinary Purchasing Company Limited Appoints a New CEO
CNW Group - Wed Oct 01, 8:00AM CDT
The Board of Directors of Veterinary Purchasing Company Limited (VPCL) today announced the appointment of a new Chief Executive Officer. Mr. Rick Culbert takes over the role from Mr. Brendan Ginty, who is retiring after 39 years of leadership.
Bioniche Life Sciences Inc. Reports Fiscal 2014 Year-End Results
PR Newswire - Fri Sep 26, 4:12PM CDT
(all figures are in Canadian dollars unless otherwise noted)
BNC.TO: 0.21 (unch)
Bioniche Life Sciences Receives Coverage as Highly Undervalued Biopharmaceutical
Marketwire - Wed Sep 17, 9:20AM CDT
Bioniche Life Sciences, Inc. (PINKSHEETS: BNHLF) (TSX: BNC), a clinical stage Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary and innovative therapies for the global human health market, has been featured in a new article that highlights this busy but "under the radar" company with quite a story to tell. Sujan Lahiri, an independent market researcher with a focus on small-cap stocks, released his in-depth analysis on Bioniche today on Seeking Alpha.
BNC.TO: 0.21 (unch)
Global N-acetylcysteine Market Report 2014-2019
M2 - Tue Sep 16, 9:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f6gj3d/global) has announced the addition of the "Global N-acetylcysteine Industry Report 2014" report to their offering. The Global N-acetylcysteine Industry Report 2014 is a professional and in-depth study on the current state of the global N-acetylcysteine industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The N-acetylcysteine market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. N-acetylcysteine industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. The report focuses on twenty industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The N-acetylcysteine industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered: - N-acetylcysteine Industry Overview - Global N-acetylcysteine Market Status Analysis - Major Regions N-acetylcysteine Market Status Analysis - Major Countries N-acetylcysteine Market Status and Analysis - Major Companies N-acetylcysteine Market Status and Analysis - N-acetylcysteine Industry Chain and Marketing Channels Analysis - N-acetylcysteine Industry Segment Market Analysis - N-acetylcysteine Industry Development Trend - N-acetylcysteine New Project Investment Feasibility Analysis - Global N-acetylcysteine Industry Research Conclusions Companies Mentioned - BASF - Bioniche Life Sciences - Cumberland Pharmaceuticals - Donboo Amino Acid - Hubei Jusheng Technology - Hubei Shengbaolai Biological Technology - Manus Aktteva Biopharma Llp - Ningbo Create-Bio Engineering - Ningbo Zhenhai Haide Amino Acid - Swacker Ag - Wuxi Enovo Chemical - Wuhan Grand Hoyo - Wuhan Hezhong Bio-Chemical - Wuhan Lullaby Pharmaceutical Chemical - Xys - Xinyi Hanling Biological Engineering - Zambon - Zhangjiagang Specom Biochemical - Zhangjiagang Huachang Pharmaceutical - Zhangjiagang Shuguang Biological For more information visit http://www.researchandmarkets.com/research/f6gj3d/global
CPIX: 5.90 (+0.04)
IIROC Trade Resumption - Bioniche Life Sciences Inc.
Newsfile Corp - Fri Aug 22, 1:12PM CDT
Trading resumes in:
IIROC Trade Halt - Bioniche Life Sciences Inc.
Newsfile Corp - Thu Aug 21, 2:29PM CDT
The following issues have been halted by IIROC:
